A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study

A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study

Bibliographic Details
Main Authors:	Bühler, Klaus, Naether, Olaf
Format:	Online
Language:	English
Published:	Informa Healthcare 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167469/

Similar Items

A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology
by: Bühler, Klaus, et al.
Published: (2014)

Managing infertility with the follitropin alfa prefilled pen injector – patient considerations
by: Bühler, Klaus
Published: (2015)

Ovulation induction with minimal dose of follitropin alfa: a case series study
by: Bruna-Catalán, Isidoro, et al.
Published: (2011)

A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility
by: Gizzo, Salvatore, et al.
Published: (2016)

A redesigned follitropin alfa pen injector for infertility: results of a market research study
by: Abbotts, Carole, et al.
Published: (2011)

Human factors engineering and design validation for the redesigned follitropin alfa pen injection device
by: Mahony, Mary C, et al.
Published: (2015)

Retrospective observational outcomes for drotrecogin alfa (activated)
by: Cameron, C, et al.
Published: (2007)

Multicentre audit of the use of drotrecogin alfa (activated) in UK critical care units
by: Rowan, K, et al.
Published: (2007)

Practical aspects of treatment with drotrecogin alfa (activated)
by: Camporota, Luigi, et al.
Published: (2007)

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
by: Sadique, M Zia, et al.
Published: (2011)

Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency
by: Rinaldi, Leonardo, et al.
Published: (2016)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
by: Laterre, Pierre-François
Published: (2007)

The safety profile of drotrecogin alfa (activated)
by: Fumagalli, Roberto, et al.
Published: (2007)

Conestat alfa for the treatment of angioedema attacks
by: Davis, Benjamin, et al.
Published: (2011)

Role of elosulfase alfa in mucopolysaccharidosis IVA
by: Regier, Debra S, et al.
Published: (2016)

Virtual strategy development in Alfa Laval
by: Mikael E., Malmgren, et al.
Published: (2009)

The Alfa Laval virtual strategy process
by: Peter, Bailliere
Published: (2010)

A large, single-centre UK registry of drotrecogin alfa-activated use
by: Macchiavello, L, et al.
Published: (2007)

Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment
by: Illingworth, Peter J, et al.
Published: (2014)

Simultaneous typing of alfa s1, beta, kappacaseins, betalactoglobulin, alfa-lactalbumin and serum albumin in cow milk by polyacrylamide gel electrophoresis
by: Sjaunja, LO, et al.
Published: (1978)

Individualized recombinant human follicle-stimulating hormone dosing using the CONSORT calculator in assisted reproductive technology: a large, multicenter, observational study of routine clinical practice
by: Naether, Olaf GJ, et al.
Published: (2015)

Alfa Laval Thermal acquires Vicarb S.A.
Published: (1999)

Agalsidase alfa (Replagal™) in the treatment of Anderson-Fabry disease
by: Pastores, Gregory M
Published: (2007)

Efficacy of Alfa EEG wave biofeedback in the management of anxiety
by: Bhat, Pookala
Published: (2010)

Update on role of agalsidase alfa in management of Fabry disease
by: Ramaswami, Uma
Published: (2011)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
by: Feriani, Mariano, et al.
Published: (2011)

Introduction: severe sepsis and drotrecogin alfa (activated)
by: Artigas, Antonio, et al.
Published: (2007)

Drotrecogin alfa (activated): down and not out, but not really in either
by: Friedrich, Jan O, et al.
Published: (2006)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
by: Choi, Goda, et al.
Published: (2006)

Introducing intellectual potential – the case of Alfa Laval
by: Carl‐Henric, Nilsson, et al.
Published: (2004)

Increasing microcirculation after drotrecogin alfa (activated)
by: Donati, A, et al.
Published: (2007)

Use of national guidelines for the introduction of Drotrecogin alfa (activated)
by: Mackenzie, S, et al.
Published: (2004)

Pathophysiology of hypophosphatasia and the potential role of asfotase alfa
by: Orimo, Hideo
Published: (2016)

Drotrecogin alfa (activated) for the treatment of severe sepsis in adults
Published: (2006)

Built‐in quality from Alfa's factory in the south
Published: (1983)

Additions to the Alfa Laval heat exchanger range
Published: (1999)

Turoctocog alfa (NovoEight®) – from design to clinical proof of concept
by: Ezban, Mirella, et al.
Published: (2014)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A
by: Chowdary, Pratima, et al.
Published: (2016)

A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders
by: Wang, Huai-Ling, et al.
Published: (2016)

Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database
by: Sato, Izumi, et al.
Published: (2014)